Articles tagged with Cancer Cells
Researchers at the University of Birmingham have successfully extracted and modified a compound from feverfew to kill chronic lymphocytic leukemia cells in laboratory experiments. The compound, parthenolide, works by increasing reactive oxygen species levels in cancer cells, causing them to die.
A new combination treatment regimen enhances the immune system's ability to kill leukemias that do not respond to standard treatments. The regimen includes a therapeutic antibody designed to attract natural killer immune cells to cancer cells, resulting in increased killing of acute lymphoblastic leukemia cells by up to 35%.
Artificial cells have been created by Imperial College London scientists that can sense changes in their surroundings and respond with drug molecules or harm removal. This breakthrough uses a simpler approach to mimic complex biological responses, making it easier to engineer artificial cells for various biotechnological applications.
Scientists have found that senescent cells stop producing nucleotides, a class of chemicals essential to keep cells young. The discovery could pave the way for new drugs to eliminate aged cells and promote healthy aging.
A team of researchers has developed a high-performance computing framework to simulate cancer treatment combinations, aiming to improve personalized medicine. The tool, called EMEWS, uses agent-based modeling and machine learning to identify optimal treatment parameters for various types of cancer.
Researchers at Emory University have identified a way to inhibit cancer cell growth by targeting the bottleneck enzyme ribonucleotide reductase. By regulating its active site, scientists hope to develop novel anticancer agents that preferentially target cancer cells.
Researchers found a common vulnerability among aneuploid cancer cells, which are bloated and overstuffed due to high intracellular protein concentrations. The team identified a molecular pathway involving proteins ART1 and Rsp5 that regulates nutrient uptake in these cells.
Researchers at Penn State College of Medicine have identified a potential therapeutic target for high-grade serous ovarian cancer cells by preventing a protein from doing its job. Inhibiting this protein led to a halt in cell division and may be an effective strategy for future therapies.
Researchers at CRCHUM found that Ran protein is essential for ovarian cancer cells to migrate and invade healthy tissues. Inhibiting Ran expression can break down RhoA, a protein necessary for cell migration, leading to a loss of cancer cells' ability to move.
Researchers at Purdue University have discovered a novel set of MYC promoter G-quadruplex stabilizers that demonstrate anticancer activity in human cancer cell cultures. The agents downregulate the expression of the MYC oncogene, which is overexpressed in cancer and associated with all aspects of cancer development.
Researchers at Hiroshima University discover that a layer of cells resembling normal stomach lining is produced by stomach cancer tissue itself, making it difficult to spot after Helicobacter pylori infection treatment. This finding highlights the need for continued check-ups even after H. pylori eradication.
A study found that a naturally occurring strain of the common cold, coxsackievirus CVA21, can target and destroy bladder cancer cells without causing harm to healthy cells. The treatment showed significant reduction in tumour burden and removal of disease in one patient after just one week.
Researchers have identified a protein, TSPYL5, that allows cancer cells to survive indefinitely. Targeting this protein may help develop new therapies for children with ALT-type cancer, which currently lacks effective treatments.
Researchers at Cold Spring Harbor Laboratory discovered that pancreatic cancer cells destroy their own mitochondria to reduce reactive oxygen species and proliferate. Inhibiting the NIX pathway may prevent cancer cells from using energy to proliferate, offering a promising new target for therapies.
Researchers develop an artificial metalloenzyme that protects a metal catalyst, allowing it to target cancer cells while sparing surrounding tissues. The system uses a sugar chain to guide the metalloenzyme to specific cells, delivering a potent anti-cancer compound.
A new study reveals that high antioxidant levels may accelerate lung cancer spread, contradicting the long-held notion that antioxidants like vitamin E prevent cancer. The research highlights a complex interplay between protein BACH1, NRF2, and heme-driven oxidative stress in facilitating cancer cell migration.
Researchers have discovered how lung cancer cells metastasize by stabilizing protein BACH1, which stimulates glucose metabolism and boosts cancer cell spreading. The studies published in Cell provide a crucial new piece of the oncological puzzle and offer a potential explanation for the Warburg effect.
Purdue University researchers have created a 3D mapping technology to monitor and track the behavior of engineered cells and tissues. The technology offers diverse options for sensing and works in moist internal body environments, providing complete isolation from electronic instruments.
Researchers have identified a protein complex regulating epithelial cell connections, shedding light on cancer proliferation. This discovery has implications for understanding diseases like asthma and inflammatory bowel disease, as well as developing targeted therapies for cancer.
Researchers at the University of Bern have determined the structure of monocarboxylate transporter 4 (MCT4), a key protein in cancer cell metabolism. The study provides insights into the molecular mechanism of MCT4 and identifies promising binding sites for inhibitors, paving the way for new cancer treatments.
A new multi-organ-on-a-chip system accurately captures chemotherapies' toxic effects on liver and other organs. The technology enables flexible testing of different organ systems, potentially leading to more accurate drug development and personalized therapies.
Researchers developed a probe that accurately traces the sigma-1 receptor on ER surfaces, showing promise for studying neurological disorders and cancer. The probe was tested on prostate cancer cells, haloperidol-sensitive signal detected.
Researchers found that administering anti-inflammatory treatments before surgery can eliminate the spread of cancer cells and promote prolonged survival in animal models. These findings suggest a potential paradigm shift in cancer treatment approaches, particularly for patients undergoing resectable cancers.
A research team created an artificially produced antibody fragment that successfully blocks the transport of antibiotics and chemotherapy agents out of cancer cells. By binding to a specific protein, the fragment prevented the protein from splitting ATP, thus stopping the transport process.
Researchers at the University of Pennsylvania School of Medicine have identified a protein called TOX as the key regulator of exhausted immune cells in cancer. The discovery could lead to new immunotherapies that target or engineer TOX to reverse exhaustion and improve immunity to infections or cancer.
Researchers have identified a new type of fibroblast in pancreatic cancer tumors that can evade immune detection. The discovery, published in Cancer Discovery, highlights the complex role of these cells in protecting cancer cells and could lead to new therapeutic strategies.
Human cells use a mechanism to protect genetic transcripts from spliceosomes, preventing damage that can lead to cancer and neurodegenerative diseases. The researchers found that the snRNA of spliceosomes migrates into the cytoplasm in human cells, unlike in yeast, where it remains in the nucleus.
Researchers identified two key chemokines, CCL5 and CXCL9, as universally implicated in T cell infiltration across all solid tumors. Their simultaneous presence is a key requirement for the engraftment of T cells and establishment of 'hot tumors.'
SMU researchers develop a new approach to treat drug-resistant prostate cancer cells using a protein inhibitor and chemotherapy. The method shows promising results, increasing sensitivity of cancer cells to chemotherapeutics without harming healthy cells.
A new approach detects mutations across many different types of normal cells by analyzing RNA sequencing data from normal tissues. The study found that 95% of individuals had at least one tissue with mutations, with higher rates in lung, esophagus, and sun-exposed skin.
Ferroptotic cancer cells can stimulate the immune system, leading to activation of anticancer immunity. However, tumor cells dying by ferroptosis can also cause suppression of an antitumor immune response, contributing to cancer progression.
Researchers suggest that sexual reproduction prevents invasion of transmissible cancer by generating genetic variation and detecting foreign cells. This theory proposes a novel explanation for the evolution of sex in multicellular organisms, shifting our understanding of evolutionary biology.
Recent advances in organoid technology are revolutionizing cancer research, allowing for personalized drug testing on individual patient cells. Meanwhile, integrating organoids with organ-on-a-chip technology may overcome control challenges and enhance physiological realism, paving the way for more advanced biomedical applications.
Hollings Cancer Center researchers used a whole-organism approach to study cell division cycles, revealing two modules that work similarly in all cell types and organs. The findings confirm previous knowledge and address new questions about the regulation of E2F transcription factors.
Researchers found that regular cells can adopt immune cell characteristics, sending warning signs when stressed or in danger. This mechanism may aid in detecting cancer cells sooner, preventing tumor formation.
Researchers observed micro-perforations in the basement membrane zone, allowing inflammatory cells to access and feed growing cancer cells. This 'window' into the cancer process enables targeting of these weak spots with cancer therapeutics.
Researchers at Université de Montrêal discovered a molecular indicator for cancer progression, enabling precision medicine. They found that SRC kinases chemically modify SOCS1, leading to uncontrolled cell proliferation in cancers.
Boosting type 1 interferon production has been shown to clear viral infections and increase immunity against cancer in an animal model. Glycolysis-derived lactate plays a critical role in limiting RLR signaling, which enables the activation of type 1 IFN production.
Researchers at the University of Edinburgh have discovered a cell-wide web that transmits signals across tiny distances, allowing cells to rapidly rewire their communication networks. This discovery could lead to new insights into diseases such as pulmonary hypertension and cancer.
Researchers at NYU Abu Dhabi have developed metal-organic trefoil knots, which can deliver metals to cancer cells and induce oxidative stress. These nanoscale molecules showed high potency in vitro and in vivo against six cancer cell lines and zebrafish embryos.
A new device forces cells through tiny channels, detecting blebbing in cancer cells to identify metastatic prostate cancer. Highly metastatic cells exhibit more blebbing than normal or less-metastatic cells.
Researchers discovered E. coli bacteria change behavior to navigate tiny obstacle courses, defying predictions of slowing progress. The study's findings have implications for biology, medicine, and robotic search-and-rescue tactics.
Researchers at Medical University of South Carolina identified a metabolic Achilles heel in cancer, exploiting glutamine addiction. A new combination treatment has shown promise in treating drug-resistant esophageal cancer cells.
Researchers at Dartmouth College and City University of Hong Kong developed a swimming robot with a light-controlled cellular engine that can perform highly-targeted drug delivery. The biohybrid device transforms its shape when exposed to skin-penetrating near-infrared light, allowing it to drive and brake through fluid environments.
A Yale study reveals how cediranib, a cancer drug of limited use, stops certain cancer cells from repairing their DNA to survive. The combination of cediranib with olaparib may deliver a lethal blow in cancers that rely on a specific DNA repair pathway.
Researchers found that targeting telomeres with oxidative stress can shorten them, leading to accelerated cellular aging and DNA instability. This could lead to potential cancer treatment strategies by stopping cancer cells from dividing.
Researchers developed cell membrane-coated nanocarriers to overcome immune clearance and biotoxicity issues. These biomimetic hybrids achieve improved biocompatibility, circulation time, and therapeutic efficiency.
A study published in ACS Central Science found that many DNA cage nanostructures are not taken up by cells, but rather degraded by enzymes outside the cell. The researchers' findings have significant implications for the use of DNA strands as a tool for delivering therapeutic agents into diseased cells.
Researchers at MD Anderson Cancer Center discovered a small molecule drug, IACS-10759, that targets metabolic reprogramming and inhibits OXPHOS, leading to marked growth inhibition in ibrutinib-resistant mantle cell lymphoma cells. The study provides hope for patients with this incurable B-cell lymphoma.
Researchers discovered that fibrinogen, a blood-clotting protein, plays a role in multiple sclerosis relapses. In a mouse model, injecting EVs containing fibrinogen activated CD8+ immune cells, leading to relapsing-remitting disease.
Researchers at Swansea University's Medical School have found that immune cells can re-programme their metabolic pathways to provide energy and building blocks when challenged. This discovery suggests that manipulating metabolism could lead to new therapies for infectious diseases and cancer.
Researchers have identified a key enzyme that helps cancer cells survive by eliminating junk RNA. Targeting this enzyme, ADAR, may lead to breakthroughs in treating various types of cancer.
Cells lacking CD13 protein can't move normally, hindering their ability to repair wounds and metastasize. Researchers discovered that CD13 acts as an organizer, gathering recycled integrin proteins at the cell membrane to enable movement.
Researchers found that cancer cells can capitalize on temporary gaps in endothelial cell layers caused by physical forces and mechanical stresses, allowing them to migrate through and colonize new organs. This opportunistic approach complements chemical signaling and enables cancer cells to spread more efficiently.
A study at UT MD Anderson Cancer Center identified a new therapeutic target in cancer cells, caseinolytic protease P (ClpP), which breaks down proteins within mitochondria. New anti-cancer agents called imipridones activate ClpP and cause cancer cell death via mitochondrial proteolysis.
Researchers have developed a computational approach to simulate the complex bioelectrical interaction at the tissue scale, enabling more accurate and capable virtual experiments of cell behavior. The technique has potential applications in treating cancer and accelerating combat wound healing.
Researchers found that MDM2 interacts with a mitochondrial protein to promote cancer cell death. Nutlin-3A enhances this interaction, helping kill cancer cells.
Researchers found that removing the ATDC gene from pancreatic cells prevented the development of pancreatic cancer in mice. The study identified ATDC as a key player in the reprogramming of adult cells into primitive, high-growth cell types, which can lead to cancer.
Researchers created SCOTfluors, a class of small fluorophores that can be attached to common metabolites and emit light in the visible to near-infrared range. This allows for the observation of metabolite trafficking in living cells without destroying them.
Researchers have engineered molecules that restrict access to heme, an oxygen-binding molecule, to slow the growth of lung cancer tumors in mice. By starving cancer cells of this essential molecule, the new approach may provide a potential new path forward in treating non-small cell lung cancer.